Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $142,650.00 in Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon sold 15,000 shares of the business’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $9.51, for a total transaction of $142,650.00. Following the sale, the director now directly owns 811,283 shares of the company’s stock, valued at approximately $7,715,301.33. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Cyrus Harmon also recently made the following trade(s):

• On Thursday, March 28th, Cyrus Harmon sold 20,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $10.97, for a total value of $219,400.00.
• On Thursday, February 29th, Cyrus Harmon sold 25,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $12.41, for a total value of $310,250.00.

Olema Pharmaceuticals Stock Performance

Shares of NASDAQ:OLMA opened at $10.07 on Friday. Olema Pharmaceuticals, Inc. has a 1-year low of $5.02 and a 1-year high of $17.79. The company has a 50 day moving average price of $11.61 and a 200 day moving average price of $12.83.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its earnings results on Monday, March 11th. The company reported ($0.49) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.49). Sell-side analysts predict that Olema Pharmaceuticals, Inc. will post -2.34 earnings per share for the current year.

Institutional Trading of Olema Pharmaceuticals

A number of hedge funds have recently made changes to their positions in OLMA. Public Employees Retirement System of Ohio acquired a new position in Olema Pharmaceuticals in the 3rd quarter valued at approximately $35,000. China Universal Asset Management Co. Ltd. acquired a new stake in Olema Pharmaceuticals during the fourth quarter valued at $89,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Olema Pharmaceuticals during the 4th quarter valued at about $130,000. SG Americas Securities LLC acquired a new stake in Olema Pharmaceuticals in the third quarter valued at approximately $142,000. Finally, Raymond James Financial Services Advisors Inc. bought a new stake in Olema Pharmaceuticals during the third quarter worth approximately $164,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently issued reports on OLMA. Citigroup initiated coverage on shares of Olema Pharmaceuticals in a report on Tuesday, January 30th. They set a “buy” rating and a $20.00 price target for the company. Capital One Financial reissued an “overweight” rating on shares of Olema Pharmaceuticals in a research note on Thursday, February 22nd. Finally, The Goldman Sachs Group assumed coverage on shares of Olema Pharmaceuticals in a research note on Tuesday, April 2nd. They issued a “buy” rating and a $24.00 price target on the stock. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $21.43.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.